BCAB

BCAB

Bioatla Inc

BioAtla, Inc. develops antibody-based therapeutics for solid tumor cancers. Key products include mecbotamab vedotin for sarcoma and lung cancer, and ozuriftabmab vedotin for melanoma. The company employs proprietary technologies for drug development.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago $2today

Score Overview

1 Year
Score
Net Growth15.08%
Net TrendGrew
Net Income Consistency
Rev Growth0.00%
Rev TrendShrank
Revenue Consistency
5 Years
Score5.1
Net Growth46.94%
Net Trend60%
Net Income Consistency
Rev Growth8x
Rev Trend20%
Revenue Consistency
All Time
Score
Net Growth-41.18%
Net Trend50%
Net Income Consistency
Rev Growth366.20%
Rev Trend17%
Revenue Consistency

See the full market ranking →

Bioatla Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 429K to $ 2M and net income went from -$ 35M to -$ 59M. Revenue increased in 1 of those 5 years; net income in 3.

Bioatla Inc currently holds a 5-year HDB Score of 5.1 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 3.38
1 Year2025-08-12
$ 18.50-81.73%
5 Years2021-08-12
$ 2.09K-99.84%
All Time2020-12-16
$ 1.55K-99.78%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 2M-$ 50M$ 1M
2025$ 2M-$ 59M$ 7M
2024$ 11M-$ 69M$ 49M
2023$ 0.00-$ 123M$ 111M
2022$ 0.00-$ 105M$ 215M
2021$ 250K-$ 95M$ 244M
IPO2020$ 429K-$ 35M$ 238M

Explore beyond BCAB

You're looking at Bioatla Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies